Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. (Q42628866)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 December 2011

Language	Label	Description	Also known as
English	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.	scientific article published on 13 December 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

phase II clinical trial

0 references

multicenter clinical trial

0 references

post-transplant lymphoproliferative disorder

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Heiner Zimmermann

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Franck Morschhauser

11

object named as

Franck Morschhauser

1 reference

Europe PubMed Central

PubMed publication ID

18 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

author name string

Stephan Oertel

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Veronique Leblond

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Monica Sender

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ruth Neuhaus

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hans Lehmkuhl

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Heinz August Horst

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Thierry Lamy

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Malte Leithäuser

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ioannis Anagnostopoulos

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Martine Raphael

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hanno Riess

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sylvain Choquet

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

German PTLD Study Group

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

European PTLD Network

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Petra Reinke

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

13 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

196-206

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttransplant lymphoma--a single-center experience of 500 liver transplantations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of PTLD with rituximab or chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interindividual variability of response to rituximab: from biological origins to individualized therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70300-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42628866&oldid=2120326212"